Out of the limelight

Several digital health players are stepping out of the public (market) eye. In the past few weeks, revenue cycle management player R1 RCM and AI scribe company Augmedix both announced they would leave the Nasdaq in take-private deals, extending a pattern of digital health delistings from Q1 2024. 23andMe's co-founder attempted to take the genetic testing firm private, amid other business pivots, though the proposal was declined by the company’s board.

Going private removes the pressures of being a publicly-traded company (e.g., shareholder management, quarterly reporting, regulatory compliance), giving teams more time to focus on product development and operations. It also offers a chance to restructure and take risks that can lead to long-term wins. However, public-to-private transitions can be complex—which means that digital health companies eyeing IPOs are taking extra steps to make sure they’re set up for public market success.

In anticipation of one of the best days of the year, we are thrilled to announce the agenda for Rock Health Summit 2024. Take a look at what you can expect to hear at this year’s event. We hope to see you there!

Headlines

Medicare Finalizes Reimbursement Rule For Breakthrough Medical Devices
Products deemed “breakthrough” get a quicker path to Medicare coverage STAT